Clinical Trial Update: Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and efficacy of OMS906 in C3 glomerulopathy and idiopathic immune complex-mediated glomerulonephritis is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• C3 Glomerulopathy
• Idiopathic Immune Complex-mediated Glomerulonephritis

Drugs mentioned

• OMS906 (OMS906)

Snippet

Sponsor: Omeros Corporation | Conditions: C3 Glomerulopathy, Idiopathic Immune Complex-Mediated Glomerulonephritis | Phase 2 | Status: RECRUITING